Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting

Abstract Amongst other immune cells, neutrophils play a key role in systemic inflammation leading to cardiovascular disease and can release inflammatory factors, including lipocalin-2 (LCN2). LCN2 drives cardiac hypertrophy and plays a role in maladaptive remodelling of the heart and has been associ...

Full description

Bibliographic Details
Main Authors: Michael E. Nakai, Joshua Denham, Priscilla R. Prestes, Nina Eikelis, Elisabeth A. Lambert, Nora E. Straznicky, Markus P. Schlaich, Murray D. Esler, Brendan J. O’Brien, Fadi J. Charchar, Gavin W. Lambert, Francine Z. Marques
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-83472-x
id doaj-371176a9aded4690970dc81a03253a7d
record_format Article
spelling doaj-371176a9aded4690970dc81a03253a7d2021-02-21T12:33:18ZengNature Publishing GroupScientific Reports2045-23222021-02-0111111210.1038/s41598-021-83472-xPlasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dietingMichael E. Nakai0Joshua Denham1Priscilla R. Prestes2Nina Eikelis3Elisabeth A. Lambert4Nora E. Straznicky5Markus P. Schlaich6Murray D. Esler7Brendan J. O’Brien8Fadi J. Charchar9Gavin W. Lambert10Francine Z. Marques11Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash UniversityDiscipline of Exercise and Sports Science, School of Health and Biomedical Sciences, RMIT UniversityFaculty of Science and Technology, Federation University AustraliaIverson Health Innovation Research Institute and Faculty of Health, Arts and Design, Swinburne University of TechnologyIverson Health Innovation Research Institute and Faculty of Health, Arts and Design, Swinburne University of TechnologyBaker Heart and Diabetes InstituteBaker Heart and Diabetes InstituteBaker Heart and Diabetes InstituteFaculty of Science and Technology, Federation University AustraliaFaculty of Science and Technology, Federation University AustraliaIverson Health Innovation Research Institute and Faculty of Health, Arts and Design, Swinburne University of TechnologyHypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash UniversityAbstract Amongst other immune cells, neutrophils play a key role in systemic inflammation leading to cardiovascular disease and can release inflammatory factors, including lipocalin-2 (LCN2). LCN2 drives cardiac hypertrophy and plays a role in maladaptive remodelling of the heart and has been associated with renal injury. While lifestyle factors such as diet and exercise are known to attenuate low-grade inflammation, their ability to modulate plasma LCN2 levels is unknown. Forty-eight endurance athletes and 52 controls (18–55 years) underwent measurement for various cardiovascular health indicators, along with plasma LCN2 concentration. No significant difference in LCN2 concentration was seen between the two groups. LCN2 was a very weak predictor or absent from models describing blood pressures or predicting athlete status. In another cohort, 57 non-diabetic overweight or obese men and post-menopausal women who fulfilled Adult Treatment Panel III metabolic syndrome criteria were randomly allocated into either a control, modified Dietary Approaches to Stop Hypertension (DASH) diet, or DASH and exercise group. Pre- and post-intervention demographic, cardiovascular health indicators, and plasma LCN2 expression were measured in each individual. While BMI fell in intervention groups, LCN2 levels remained unchanged within and between all groups, as illustrated by strong correlations between LCN2 concentrations pre- and 12 weeks post-intervention (r = 0.743, P < 0.0001). This suggests that circulating LCN2 expression are stable over a period of at least 12 weeks and is not modifiable by diet and exercise.https://doi.org/10.1038/s41598-021-83472-x
collection DOAJ
language English
format Article
sources DOAJ
author Michael E. Nakai
Joshua Denham
Priscilla R. Prestes
Nina Eikelis
Elisabeth A. Lambert
Nora E. Straznicky
Markus P. Schlaich
Murray D. Esler
Brendan J. O’Brien
Fadi J. Charchar
Gavin W. Lambert
Francine Z. Marques
spellingShingle Michael E. Nakai
Joshua Denham
Priscilla R. Prestes
Nina Eikelis
Elisabeth A. Lambert
Nora E. Straznicky
Markus P. Schlaich
Murray D. Esler
Brendan J. O’Brien
Fadi J. Charchar
Gavin W. Lambert
Francine Z. Marques
Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting
Scientific Reports
author_facet Michael E. Nakai
Joshua Denham
Priscilla R. Prestes
Nina Eikelis
Elisabeth A. Lambert
Nora E. Straznicky
Markus P. Schlaich
Murray D. Esler
Brendan J. O’Brien
Fadi J. Charchar
Gavin W. Lambert
Francine Z. Marques
author_sort Michael E. Nakai
title Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting
title_short Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting
title_full Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting
title_fullStr Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting
title_full_unstemmed Plasma lipocalin-2/NGAL is stable over 12 weeks and is not modulated by exercise or dieting
title_sort plasma lipocalin-2/ngal is stable over 12 weeks and is not modulated by exercise or dieting
publisher Nature Publishing Group
series Scientific Reports
issn 2045-2322
publishDate 2021-02-01
description Abstract Amongst other immune cells, neutrophils play a key role in systemic inflammation leading to cardiovascular disease and can release inflammatory factors, including lipocalin-2 (LCN2). LCN2 drives cardiac hypertrophy and plays a role in maladaptive remodelling of the heart and has been associated with renal injury. While lifestyle factors such as diet and exercise are known to attenuate low-grade inflammation, their ability to modulate plasma LCN2 levels is unknown. Forty-eight endurance athletes and 52 controls (18–55 years) underwent measurement for various cardiovascular health indicators, along with plasma LCN2 concentration. No significant difference in LCN2 concentration was seen between the two groups. LCN2 was a very weak predictor or absent from models describing blood pressures or predicting athlete status. In another cohort, 57 non-diabetic overweight or obese men and post-menopausal women who fulfilled Adult Treatment Panel III metabolic syndrome criteria were randomly allocated into either a control, modified Dietary Approaches to Stop Hypertension (DASH) diet, or DASH and exercise group. Pre- and post-intervention demographic, cardiovascular health indicators, and plasma LCN2 expression were measured in each individual. While BMI fell in intervention groups, LCN2 levels remained unchanged within and between all groups, as illustrated by strong correlations between LCN2 concentrations pre- and 12 weeks post-intervention (r = 0.743, P < 0.0001). This suggests that circulating LCN2 expression are stable over a period of at least 12 weeks and is not modifiable by diet and exercise.
url https://doi.org/10.1038/s41598-021-83472-x
work_keys_str_mv AT michaelenakai plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT joshuadenham plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT priscillarprestes plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT ninaeikelis plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT elisabethalambert plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT noraestraznicky plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT markuspschlaich plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT murraydesler plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT brendanjobrien plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT fadijcharchar plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT gavinwlambert plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
AT francinezmarques plasmalipocalin2ngalisstableover12weeksandisnotmodulatedbyexerciseordieting
_version_ 1724257900648464384